Risk classifier | Cases | Controls | 10-Year risk | |
---|---|---|---|---|
 |  |  | % | 95% CI |
Tamoxifen treated | ||||
Recurrence Score (55 cases and 150 controls) | ||||
   Low (<18) | 29% | 63% | 2.8 | (1.7–3.9) |
   Intermediate (18–30) | 40% | 23% | 10.7 | (6.3–14.9) |
   High (≥31) | 31% | 13% | 15.5 | (7.6–22.8) |
Tumor size (55 cases and 150 controls) | ||||
   ≤1 cm | 16% | 31% | 3.6 | (1.7–5.5) |
   1.1–2 cm | 44% | 43% | 5.8 | (3.7–7.8) |
   >2 cm | 40% | 26% | 9.3 | (5.5–13.1) |
Tumor grade (55 cases and 150 controls) | ||||
   Well | 11% | 33% | 2.1 | (0.7–3.5) |
   Moderate | 51% | 46% | 6.9 | (4.7–9.0) |
   Poor | 38% | 21% | 9.9 | (6.0–13.7) |
Tumor size and grade (55 cases and 150 controls) | ||||
   ≤2 cm and well or ≤1 cm and moderate | 15% | 43% | 2.5 | (1.2–3.9) |
   >2 cm and well, or 1.1–2 cm and moderate, or ≤2 cm and poor | 49% | 39% | 7.2 | (4.9–9.5) |
   >2 cm and moderate/poor | 36% | 18% | 11.5 | (6.6–16.2) |
Recurrence Score, tumor size and grade | ||||
   Recurrence Score low <18 (16 cases and 95 controls) |  |  |  |  |
≤2 cm and well or ≤1 cm and moderate | 6% | 46% | 0.4 | (0.0–1.0) |
>2 cm and well, or 1.1–2 cm and moderate, or ≤2 cm and poor | 63% | 39% | 4.1 | (2.0–6.2) |
>2 cm and moderate/poor | 31% | 15% | 6.9 | (1.8–11.7) |
   Recurrence Score intermediate 18–30 (22 cases and 35 controls) |  |  |  |  |
≤2 cm and well or ≤1 cm and moderate | 32% | 51% | 6.8 | (2.6–10.9) |
>2 cm and well, or 1.1–2 cm and moderate, or ≤2 cm and poor | 45% | 29% | 21.9 | (5.0–35.8) |
>2 cm and moderate/poor | 23% | 20% | 13.5 | (1.2–24.2) |
   Recurrence Score high ≥31 (17 cases and 20 controls) |  |  |  |  |
≤2 cm and well or ≤1 cm and moderate | 0% | 10% | 12.2 | (0.0–31.0) |
>2 cm and well, or 1.1–2 cm and moderate, or ≤2 cm and poor | 41% | 60% | 10.9 | (2.9–18.3) |
>2 cm and moderate/poor | 59% | 30% | 28.9 | (7.4–45.3) |
Tamoxifen untreated | ||||
Recurrence Score (110 cases and 251 controls) | ||||
   Low (<18) | 36% | 64% | 6.2 | (4.5–7.9) |
   Intermediate (18–30) | 29% | 19% | 17.8 | (11.8–23.3) |
   High (≥31) | 35% | 18% | 19.9 | (14.2–25.2) |
Tumor size (110 cases and 251 controls) | ||||
   ≤1 cm | 29% | 39% | 8.5 | (6.0–10.9) |
   1.1–2 cm | 41% | 45% | 10.4 | (7.8–12.9) |
   >2 cm | 30% | 16% | 16.4 | (11.4–21.0) |
Tumor grade (110 cases and 251 controls) | ||||
   Well | 15% | 33% | 5.5 | (3.4–7.4) |
   Moderate | 49% | 52% | 11.2 | (8.6–13.8) |
   Poor | 35% | 15% | 22.5 | (15.9–28.6) |
Tumor size and grade (110 cases and 251 controls) | ||||
   ≤2 cm and well or ≤1 cm and moderate | 27% | 50% | 6.2 | (4.3–8.0) |
   >2 cm and well, or 1.1–2 cm and moderate, or ≤2 cm and poor | 45% | 37% | 14.2 | (10.8–17.4) |
   >2 cm and moderate/poor | 27% | 13% | 19.1 | (13.2–24.7) |
Recurrence Score, tumor size and grade | ||||
   Recurrence Score low <18 (40 cases and 160 controls) |  |  |  |  |
≤2 cm and well or ≤1 cm and moderate | 35% | 63% | 3.0 | (1.7–4.3) |
>2 cm and well, or 1.1–2 cm and moderate, or ≤2 cm and poor | 48% | 31% | 11.0 | (7.0–14.8) |
>2 cm and moderate/poor | 17% | 6% | 20.2 | (6.1–32.2) |
   Recurrence Score intermediate 18–30 (32 cases and 47 controls) |  |  |  |  |
≤2 cm and well or ≤1 cm and moderate | 34% | 38% | 17.0 | (8.2–24.9) |
>2 cm and well, or 1.1–2 cm and moderate, or ≤2 cm and poor | 38% | 34% | 20.9 | (10.2–30.4) |
>2 cm and moderate/poor | 28% | 28% | 22.0 | (9.3–32.9) |
   Recurrence Score high ≥31 (38 cases and 44 controls) |  |  |  |  |
≤2 cm and well or ≤1 cm and moderate | 13% | 14% | 25.0 | (7.9–39.0) |
>2 cm and well, or 1.1–2 cm and moderate, or ≤2 cm and poor | 50% | 59% | 21.0 | (13.8–27.5) |
>2 cm and moderate/poor | 37% | 27% | 25.3 | (15.1–34.3) |